Physician profile
Brian Blair
NPI 1407846868
$2,619.25
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $730 · 2021: $892 · 2022: $414 · 2023: $67.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347.71 | 2020-2022 | |
| Astellas Pharma US INC | $218.21 | 2019-2021 | |
| Amgen INC. | $209.92 | 2019-2022 | |
| Lilly USA, LLC | $209.29 | 2020-2022 | |
| Pfizer INC. | $200.22 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.80 | 2019-2022 | |
| Novo Nordisk INC | $129.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $122.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $97.47 | 2019-2021 | |
| Allergan, INC. | $94.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $90.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $85.12 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $61.51 | 2019-2020 | |
| Gilead Sciences, INC. | $54.84 | 2022-2023 | Epclusa |
| Upsher-Smith Laboratories LLC | $50.46 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $46.68 | 2019 | |
| Nestle Healthcare Nutrition INC. | $41.10 | 2021 | |
| Esperion Therapeutics, INC. | $38.60 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.60 | 2022 | |
| Alkermes, INC. | $26.08 | 2022-2023 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $21.50 | 2022 | |
| Abbott Laboratories | $19.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.74 | 2021 | |
| Phadia US INC. | $16.61 | 2021 | |
| Genentech USA, INC. | $16.13 | 2021 | |
| Adlon Therapeutics L.P. | $15.18 | 2021 | |
| Philips North America LLC | $14.62 | 2023 | |
| Avanir Pharmaceuticals, INC. | $13.96 | 2020 | |
| Eisai INC. | $13.25 | 2020 | |
| Zyla Life Sciences, INC. | $12.22 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.